Small molecule
Arbaclofen placarbil is an oral prodrug formulation tested in immediate-release, sustained-release and modified-release tablet and capsule forms. It is studied in gastroesophageal reflux disease, alcohol use disorder and healthy volunteers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02511886 | Phase 2 | Alcohol Use Disorder | Completed | INDV |
| NCT00838396 | Phase 2 | GERD | Completed | INDV |
| NCT03058237 | Phase 1 | Healthy Volunteers | Completed | INDV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alcohol Use DisorderGERDHealthy Volunteers
Updated Oct 18, 2026.